Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.99 | N/A | -107.29% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.99 | N/A | -107.29% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to advancing their pipeline despite the lack of financial guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company is focusing on its ongoing clinical trials and product development.
Krystal Biotech's earnings report showed a significant loss per share, which contributed to a sharp decline in stock price. The lack of revenue figures and guidance left investors uncertain about the company's financial trajectory. The stock's 12.28% drop reflects investor concerns about the company's performance and future outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NRG ENERGY INC
May 6, 2022